Patient characteristics
| . | Prophylactic granulocyte transfusions: cohort A; n = 83 . | No prophylactic granulocyte transfusions: cohort B; n = 142 . | P . |
|---|---|---|---|
| Median age, y (range) | 44 (13-68) | 46 (17-70) | .85* |
| Diagnosis | .052† | ||
| Acute leukemia | 36 (43.4%) | 61 (43.0%) | |
| Non-Hodgkin lymphoma | 17 (20.5%) | 37 (26.0%) | |
| Chronic myelogeneous leukemia | 17 (20.5%) | 18 (12.7%) | |
| Other | 13 (14.6%) | 26 (18.3%) | |
| GVHD | |||
| Grades I-IV | 59 (71.0%) | 94 (66.2%) | .64† |
| Grades III-IV | 10 (12.0%) | 14 (9.8%) | .68† |
| . | Prophylactic granulocyte transfusions: cohort A; n = 83 . | No prophylactic granulocyte transfusions: cohort B; n = 142 . | P . |
|---|---|---|---|
| Median age, y (range) | 44 (13-68) | 46 (17-70) | .85* |
| Diagnosis | .052† | ||
| Acute leukemia | 36 (43.4%) | 61 (43.0%) | |
| Non-Hodgkin lymphoma | 17 (20.5%) | 37 (26.0%) | |
| Chronic myelogeneous leukemia | 17 (20.5%) | 18 (12.7%) | |
| Other | 13 (14.6%) | 26 (18.3%) | |
| GVHD | |||
| Grades I-IV | 59 (71.0%) | 94 (66.2%) | .64† |
| Grades III-IV | 10 (12.0%) | 14 (9.8%) | .68† |